

MOMOZ F

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only
Abbreviated Prescribing information for **MOMOZ F** [Mometasone Furoate with Fusidic Acid
Ointment.]

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

MECHANISM OF ACTION: *Mometasone Furoate* Mometasone Furoate exhibits marked anti-inflammatory activity and marked antipsoriatic activity in standard animal predictive models. *Fusidic acid* Fusidic acid belongs to a unique group of antibiotics, the fustians, which act to inhibit bacterial protein synthesis by blocking the lengthening of factor G. This is to prevent it from associating with ribosomes and GTP, thus preventing energy supply to the synthesis process.

INDICATIONS: For the treatment of dermatoses where secondary bacterial and/or candidial infection is present.

DOSAGE AND ADMINISTRATION: As directed by Physician. For external use only.

CONTRAINDICATION: Momoz F is contraindicated in facial rosacea, acne vulgaris, skin atrophy, perioral dermatitis, perianal and genital pruritus, napkin eruptions, bacterial (e.g. impetigo, pyodermas), viral (e.g. herpes simplex, herpes zoster and chickenpox verrucae vulgares, condylomata acuminata, molluscum contagiosum), parasitical and fungal (e.g. candida or dermatophyte) infections, varicella, tuberculosis, syphilis or post vaccine reactions. Momoz F should not be used on wounds or on skin which is ulcerated. Momoz F should not be used in patients who are hypersensitivity to the active substances or to any of the excipients.

WARNINGS & PRECAUTIONS: Glucocorticoids can change the appearance of some lesions and make it difficult to establish an adequate diagnosis and can also delay the healing. Bacterial resistance among *Staphylococcus aureus* has been reported to occur with the use of topical MOMOZ F. As with all antibiotics, extended or recurrent use may increase the risk of developing antibiotic resistance.

DRUG INTERACTIONS: NA.

ADVERSE REACTIONS: Infection, furuncle, folliculitis, paraesthesia, burning sensation, dermatitis contact, skin hypopigmentation, hypertrichosis, skin striae, dermatitis acneiform, skin atrophy, pruritus, application site pain, application site reactions, vision blurred, hypersensitivity, conjunctivitis, dermatitis (including dermatitis contact, eczema) rash* pruritus erythema, and angioedema urticaria blister

MARKETED BY:

TORRENT
PHARMA

TORRENT PHARMACEUTICALS LTD.

IN/MOMOZ F 0.1% w/w, 2.0 % w/w/FEB-26/02/ABPI

(Additional information is available on request)